CureVac
CVAC
CVAC was delisted on the 5th of January, 2026.
43 hedge funds and large institutions have $341M invested in CureVac in 2020 Q3 according to their latest regulatory filings, with 43 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.27% more ownership
Funds ownership: 0% → 4.27% (+4.3%)
8% more call options, than puts
Call options by funds: $14.9M | Put options by funds: $13.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$217M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$67.1M |
| 3 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$24.3M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$20.7M |
| 5 |
Millennium Management
New York
|
+$17M |
Top Sellers
CVAC Hedge Fund Activity: Q3 2020 in Review
43 of the 4,905 institutional investors tracked by Wall St. Rank reported a position in CureVac (CVAC) for Q3 2020, worth a combined $341M.
Buyers outnumbered sellers: 43 funds opened new CVAC positions and 0 closed out — a net gain of 43 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baillie Gifford & Co, opening a new position worth an estimated $217M.
- 43 institutional investors held CureVac (CVAC) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $341M of CureVac stock for Q3 2020.
- 43 funds opened new CureVac positions in Q3 2020 and 0 closed out, a net change of +43 holders.
- The largest CureVac buyer in Q3 2020 was Baillie Gifford & Co, an estimated $217M added.
Based on aggregated 13F filings for Q3 2020.